← Back to Clinical Trials
Recruiting Phase 2, Phase 3 NCT05535738

Using a Contact Dermatitis Model With Biologic Medications to Study Skin Inflammation

Trial Parameters

Condition Skin Inflammation
Sponsor Wei-Che Ko
Study Type INTERVENTIONAL
Phase Phase 2, Phase 3
Enrollment 45
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2022-11-15
Completion 2027-01-01
Interventions
Squaric Acid Dibutyl EsterKnown patch test allergensDupilumab

Brief Summary

The purpose of this study is to answer: how do inflammation and anti-inflammatory skin therapies work in the skin? Inflammation is a protective response from the body's immune system to injury, disease, or irritation. It is a process by which your body's white blood cells and the things they make protect you from infection from outside invaders such as bacteria and viruses.

Eligibility Criteria

Inclusion Criteria: * Healthy adult subjects over the age of 18 years with no skin diseases * Patients with dermatologic conditions such as atopic dermatitis, history of localized non-melanoma, keratinocytic skin cancer * Patients with previous clinical patch testing * UMass Medical School students and employees are eligible to participate. * Non-English-speaking individuals are also eligible with the assistance of an interpreter and an approved short form consent in the appropriate language. Exclusion Criteria: * Adults unable to give consent * History of the following specific dermatologic conditions (which would be confounders due to their particular immunologic etiologies, specifically the TNFa and IL-17 pathways which oppose the Th2 pathway): pityriasis rubra pilaris and psoriasis * Patients actively receiving whole body phototherapy * Patients actively receiving systemic broad-spectrum immunosuppression (prednisone, mycophenolate mofetil, azathioprine, methotrexate) * Any history

Related Trials